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a b s t r a c t
Amyloidosis is a systemic disorder characterized by the deposition of mis-folded protein
molecules within various organs. Cardiac involvement may be the presenting feature of this
condition or may be identiﬁed incidentally during investigation for amyloidosis affecting
other organs. The presence and severity of cardiac involvement varies with the type of
amyloidosis.
Irrespective of the subtype, patients with cardiac amyloidosis usually present with
symptoms of heart failure with echocardiography showing features of restrictive cardiomy-
opathy. The usual cardiac symptoms noted in patients with amyloidosis include dyspnea,
peripheral edema, and palpitations secondary to arrhythmias.1 Chest pain secondary to
myocardial ischemia is an unusual presentation of cardiac amyloidosis, and is attributed to
the deposition of protein molecules in the coronary microvasculature. We describe the case
of a patient who presented with recurrent cardiac ischemia secondary to amyloidosis.
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A 75-year-old man was admitted to the coronary care unit with
symptoms of chest pain for the past 4 h. He gave a history of
exertional chest pain and breathlessness over the previous 3
months. His coronary risk factors included dyslipidemia, and
he was an ex-smoker. There was no signiﬁcant family history
and he had no signiﬁcant medical or surgical conditions. On
examination, he was hemodynamically stable. Precordial
auscultation revealed normal heart sounds with no added
features and there was no dependent edema or visible jugular* Corresponding author.
E-mail address: anish26g@gmail.com (A. George).
http://dx.doi.org/10.1016/j.ihj.2015.08.029
0019-4832/# 2015 Published by Elsevier B.V. on behalf of Cardiologicavenous pulse. Examination of other systems did not show any
signiﬁcant abnormalities.
His initial ECG showed ST-segment depression involving
precordial leads V4, V5, and V6 (Fig. 1a). His chest X-ray
was unremarkable with no features of pulmonary edema.
Serial cardiac markers showed a rise in the level of troponin
T from an initial value of 50–73 after 12 h. The patient
was managed as non-ST-segment elevation acute coronary
syndrome (NSTE-ACS) and also received intravenous
nitrate infusion and morphine, and his pain subsided.
Repeat ECG showed resolution of the dynamic changes
noted initially (Fig. 1b) Serial cardiac markers showed a risel Society of India.
Fig. 1 – ECG at admission demonstrating ST changes (a), and ECG at baseline once symptoms have settled (b).
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12 h.
Coronary angiography (Fig. 2a, b) demonstrated nonob-
structive left anterior descending (LAD) and right coronary
artery (RCA) disease. His echocardiogram showed mild-
moderate mitral regurgitation with normal biventricular size
and function. He developed further chest pain in the ward
the day after the coronary angiography, with ECG showing
ST-segment depression in V4 to V6. A repeat angiography
was performed with intravascular ultrasound and optic
coherence tomography (OCT) to assess the severity of the
LAD and RCA lesions. This conﬁrmed that these were only
mild and nonobstructive, with no evidence of focal plaque
rupture. During the procedure, coronary spasm was noted in
the mid RCA, which resolved with intracoronary nitrates. It
was felt that the patient's symptoms could be secondary to
coronary spasm and he was discharged the following day on
medications including oral nitrate and calcium channel
blocker.Fig. 2 – Coronary angiography demonstrating nonobstructed cor
basal inferior and inferoseptal contrast enhancement (c, d).He presented again the following week with further chest
pain, shortness of breath, orthopnea, and paroxysmal nocturnal
dyspnea. While his clinical examination did not reveal any new
ﬁndings, chest X-ray showed features of pulmonary vascular
congestion and ECG again showed dynamic ST depression
involving v4 to v6. His blood tests revealed a troponin T of 1050
and NT-pro BNP of 5042. A diagnosis of NSTE-ACS was made.
Repeat echocardiogram showed mild impairment of his left
ventricular (LV) function with an ejection fraction (EF) of 42%
(Fig. 3a). A cardiac MR was performed, which also demonstrat-
ed mild LV impairment. T2-weighted images showed in-
creased signal in the mid to apical anteroseptal wall. However,
it did not reveal any evidence of contrast enhancement to
suggest inﬁltration, ﬁbrosis, or previous infarction; and there
were no features of myocarditis (Fig. 2c, d). The patient
responded to standard heart failure treatment including
diuretics and was subsequently discharged.
The patient was readmitted a week later with further chest
pain and breathlessness with a troponin T of 111 and 118 atonaries (a, b), and Cardiac MRI showing nonspecific patchy
Fig. 3 – Echocardiographic apical 4-chamber image (a), and Technetium99m PYP scan showing increased cardiac uptake (b, c,
d).
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gram showed moderate LV impairment with an EF of 35%.
A repeat cardiac MR was hence performed, which conﬁrmed
moderate LV impairment. It also showed mild wall thinning
in basal inferior and inferoseptal wall extending to the
mid LV with patchy contrast enhancement within the
basal inferoseptal wall. A cardiomyopathy screening was
performed.
Urine electrophoresis identiﬁed the presence of Bence
Jones protein type K. Plasma electrophoresis showed a
signiﬁcantly elevated kappa to lambda ratio at 129.35 (0.26–
1.65). Bone marrow aspirate cytology revealed small mono-
clonal kappa restricted plasma cells, suggestive of plasma cell
dyscrasia. Bone marrow biopsy demonstrated active marrow
with no evidence of myeloma; however, there were 7% plasma
cells and occasional Mott cells. An abdominal fat biopsy was
performed, which was also analyzed at the National Amyloid
Centre, London. The presence of amyloid was demonstrated
by the staining of amorphous material with Congo red that
displayed apple-green birefringence when viewed under high-
intensity cross-polarized light. Amyloid deposits were present
throughout. Histochemical staining of the amyloid deposits
was performed using monospeciﬁc antibodies reactive with
serum amyloid A protein (SAA), transthyretin (TTR), and with
kappa and lambda immunoglobulin light chains. The amyloid
stained with antibodies to kappa light chains.
A radionucleotide uptake scan (99mTechnetium PYP)
showed extensive uptake of 99mTc within the heart that
was equal to or more than that of sternal uptake (grade: 3–4),
which was suggestive of cardiac amyloidosis (Fig. 3b, c, d).
2. Discussion
Amyloidosis is a rare systemic disorder, with an annual
incidence of 1–5 cases per 100,000 people, and is characterized
by deposition of abnormal amyloid ﬁbrils in various tissues
altering their normal physiological function.1,2 Amyloidosis AL
is the commonest type of amyloidosis diagnosed, and is
associated with cardiac involvement of variable extent in
almost 70% of the cases.3 The disease typically presents as a
restrictive cardiomyopathy secondary to interstitial amyloiddeposition; however, it can uncommonly present with ische-
mic symptoms.4
The pathophysiology, behind this presentation, is the
progressive luminal narrowing of small intramural coronary
arteries caused by amyloid deposition in the arterial vessel
wall resulting in myocardial ischemia and impairment.5 The
patient typically presents with ischemic chest pain, ECG
changes, and a rise in cardiac marker, and respond to
antianginal therapy. A retrospective study involving histo-
pathological review of myocardial tissue from 98 patients with
AL amyloidosis showed that 66% patients had intramural
amyloid deposits. However, only 25% of these patients had any
symptoms suggestive of ischemia.5
The extent of vascular involvement in cardiac amyloidosis
is variable and depends on the type of amyloidosis. A study
looking at the endomyocardial biopsy samples of 100 patients
with cardiac amyloidosis showed that vascular involvement
was more common in AL amyloidosis (88%) compared to
patients with senile amyloidosis (27%).6,7 There is, however,
considerable variation in the extent of vascular involvement
amongst patients. Literature review suggests that amyloidosis
can sometimes be conﬁned to the intramural coronary
arteries, with minimal or no evidence of interstitial involve-
ment, as in this case.5–7 These cases are rare, making up only
1–2% of patients with cardiac amyloidosis.1 The prognostic
signiﬁcance of amyloid deposits in the intramural coronaries
remains unclear. While it can be argued that this results in
ischemia and subsequent infarction with myocardial im-
pairment, one study did not ﬁnd any signiﬁcant difference in
the median survival interval from diagnosis to either death or
transplant between patients with intramural coronary amy-
loidosis and patients without evidence of intramural amyloid
deposition.5
Diagnosis, in this subgroup (without signiﬁcant interstitial
involvement), can be challenging since echocardiographic and
cardiac MR ﬁndings are nonspeciﬁc. Similarly, the mild
elevation left ventricular ﬁlling pressures, which may be
noted in cardiac catheterization, are nonspeciﬁc. Coronary
angiography is typically normal as the inﬁltration is predomi-
nantly microvascular. Consequently, the diagnosis of this
form of cardiac amyloid is often delayed. The prognosis of AL
amyloidosis depends on the extent of cardiac involvement and
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prognostic markers.8
Management of cardiac amyloidosis AL involves manage-
ment of heart failure and agents that suppress the underlying
plasma cell dyscrasia. While the former includes standard
heart failure therapies like ﬂuid and salt restriction, diuretics,
spironolactone, and beta-blockers, the latter involves chemo-
therapeutic agents. Intensive treatment using melphalan-
dexamethosone based regimens coupled with autologous
stem cell transplantation (ASCT) has been known to improve
median survival.9 In younger patients with advanced heart
failure due to AL amyloidosis, cardiac transplantation fol-
lowed by high-dose melphalan-dexamethasone and ASCT has
shown some beneﬁt; however, this option is restricted by
scarcity of donors and transplant-associated complications.10
Recent introduction of the protease inhibitor bortezomib to a
dexamethoasone and cyclophosphamide based regime has
demonstrated good response rates even in previously refrac-
tive cases and is currently considered as the standard regime
in most centres.11,12 More recently, monoclonal antibodies,
which identify an epitome expressed in the AL light chains
thereby enabling its clearance from circulation, has been
isolated; however, these agents are still in the early phases of
development.13,14
Similarly, management of transthyretin-related (TTR) cardi-
ac amyloidosis involves suppression of TTR formation. Al-
though liver transplantation, especially in the familial subtype,
is the treatment of choice in these patients, in the recent years,
therapeutic strategies involving potential disease modifying
agents have emerged. The most promising amongst these are
the TTR tetramer stabilizers and the RNA inhibitors. The TTR
tetramer stabilizers bind to the transthyretin tetramer, thereby
stabilizing it and preventing its dissociation into monomeric
amyloid ﬁbrils. Diﬂunisal, a nonsteroidal anti-inﬂammatory
agent, and tafamidis, which is currently indicated for use in
early polyneuropathy associated with hereditary TTR amyloid-
osis, work by binding to the tetramer and maintaining its
stability.14–16 The RNA inhibitors, on the other hand, inhibit the
synthesis of TTR (wild type and variant) in the liver. Small
interfering RNA (siRNA) agents, like patisiran and revusiran,
inhibit speciﬁc mRNA sequences resulting in reduced produc-
tion of amyloidogenic proteins by 80%. Similarly, antisense
oligonucleotide agents, which are short synthetic nucleotide
chains, inhibit TTR protein synthesis by binding to the RNA.14,17
Despite recent advances in the management of cardiac
amyloidosis, the long-term prognosis of these patients
remains poor, especially if there has been a delay in diagnosis.
It is hence important to consider amyloidosis as a potential
diagnosis in patients presenting with ACS, with no identiﬁable
cause following coronary angiography and imaging by
echocardiography and Cardiac MR.Conﬂict of interest
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